ART (antiretroviral therapy) is the daily medication that keeps HIV suppressed. For most people in 2026, it's one pill, once a day. It doesn't cure HIV — but taken consistently, it does something arguably more useful: it drives the virus to undetectable levels and makes sexual transmission impossible.
Here's exactly how that works, what the timeline looks like, and what you actually need to do.
🔩 What ART Does (The Short Version)
HIV replicates by hijacking your CD4 cells and using them as factories to churn out copies of itself. ART blocks different stages of that process — different drugs in the regimen target different steps in the replication cycle. The result: HIV can't copy itself, levels in your blood drop toward zero, and your immune system stops taking the hit.
The goal isn't to clear the virus entirely — HIV hides in reservoirs that current medicine can't reach. The goal is suppression: driving the viral load so low your tests can't find it. That level is called undetectable, typically defined as fewer than 50 copies per millilitre of blood.
At undetectable: you cannot sexually transmit HIV. That's not a maybe — it's the conclusion of three large studies across tens of thousands of condomless sex acts with zero transmissions.
💊 The Regimen: What You're Actually Taking
For the vast majority of people starting ART in 2026, this is a single tablet, once a day. Not a cocktail, not a complicated schedule. One tablet.
Modern first-line regimens pack two or three antiretroviral drugs into a single pill — commonly combinations like bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) or dolutegravir-based alternatives. Your doctor picks based on your baseline resistance tests, your other medications, and your kidney and liver function at diagnosis.
The one thing that isn't negotiable: you take it every day. Not a course that ends when you feel better. This is a daily commitment, ongoing. Missing doses allows the virus to rebound. Consistent missed doses over weeks can cause resistance — and that narrows your future treatment options in ways that matter. The pill is simple. The consistency is the actual work.
⚠️ Dealing With Side Effects
For most people, the first couple of weeks on ART involve some adjustment — mild nausea, headaches, or vivid dreams are the most common, particularly with dolutegravir-based regimens. This is your body adapting to a new drug. For most people it resolves within 2–4 weeks. Here's how to manage it in the meantime.
Don't stop taking the pill. This is the one non-negotiable. Stopping abruptly gives the virus an opportunity to rebound and build resistance. A temporary headache is manageable; burning through your best medication options because you didn't talk to your doctor is a much bigger problem.
Play with the timing. Nausea is often dose-related rather than drug-related. Many people find taking the pill right before bed or with a substantial meal eliminates morning nausea entirely. If the pill is affecting your sleep, try shifting the dose to morning instead. There's usually flexibility here.
Log what's happening. Don't arrive at your check-up with a vague sense of "feeling off." Note exactly what you experienced, when it started relative to taking the pill, and how long it lasted. Concrete data is what lets your doctor actually help you.
Talk to your doctor — they have options. If side effects are persistent or significantly affecting your day, say so. Prescribing something to manage symptoms while your body adjusts is routine, as is switching regimens if the first choice genuinely doesn't suit you. There are dozens of modern combinations available; finding the one that works for you is a normal part of the process, not a complication.
🔬 The Timeline: When ART Actually Protects You
Taking ART does not make you undetectable on day one. Your viral load drops progressively over weeks and months as the drugs suppress replication. Three to six months is the real timeline to reach confirmed undetectable.
Here's how that sits against the other HIV prevention tools:
| Tool | When protection kicks in |
|---|---|
| Oral PrEP (daily TDF/FTC) | 7 days |
| Injectable PrEP (Cabotegravir / Apretude) | After the second injection (~2 months in) |
| ART → U=U | 3–6 months + confirmed blood test |
The ART timeline isn't a flaw in the medication — it's just how viral suppression biology works. HIV doesn't vanish overnight; it gets driven down progressively. Your doctor checks viral load at around 4 weeks (to confirm the drugs are working) and again at 3 months. When that test comes back undetectable and stays there — that's when U=U applies.
The blood test is the proof. Your intention to take your meds isn't the proof. The test is.
⏳ The Window: Before You're Confirmed Undetectable
In that first 3–6 months, you're on ART but your viral load hasn't been confirmed suppressed yet. That's a real distinction — for you and for any partners.
During this window, the practical approach is straightforward:
- Talk to partners. A partner who knows you're 2 months in and waiting on your first undetectable result can make their own informed call — whether that's using their PrEP, condoms, or both. Giving them that information is what actually reduces risk; keeping them in the dark doesn't protect anyone.
- Your STI exposure risk hasn't changed. ART only handles HIV. Gonorrhoea, chlamydia, syphilis — none of those care about your viral load. Keep testing on your regular schedule.
- This isn't a permanent state. It's a waiting period. Once you hit sustained undetectable, the picture changes completely.
🟢 After You're Undetectable: Keeping It That Way
Reaching undetectable is the beginning of a routine, not the end of one. Staying there requires two things.
Consistent daily adherence. Modern ART is forgiving — a single missed dose doesn't instantly bounce your viral load back. But missing doses regularly over days or weeks will. If adherence is getting hard — travel, mental health, life — talk to your clinic before it becomes a problem. There are injectable long-acting ART formulations (CAB+RPV, given monthly or every two months) for people who find daily pills genuinely difficult. Ask if they're available in your country.
Regular viral load monitoring. Once you're stable and confirmed undetectable, this is usually every 3–6 months — a blood draw, some numbers, a quick conversation. It confirms the suppression is holding. Without those checks, U=U is an assumption, not a fact. The monitoring is what makes it real.
🔬 The Two Numbers: Viral Load and CD4
Your ongoing health on ART is tracked through two values.
Viral load (copies/mL) is the main one. The target is undetectable (<50 copies/mL, or <20 on some platforms). This is the number that determines U=U, and the one you'll be most focused on.
CD4 count (cells/mm³) measures your immune system's health. Normal range is 500–1,500. HIV depletes CD4 cells over time; ART lets them recover. At diagnosis, your count tells your doctor how far things had progressed — if it's below 200, they'll be more cautious about certain opportunistic infections while you're early in treatment. Once you're stably suppressed and your CD4 is comfortably above 500, it becomes less central — viral load is the number that runs the show from that point.
CD4 counts fluctuate naturally — even in HIV-negative people — shifting with minor illness, stress, time of day, and lab variation. A single reading above or below your previous result isn't cause for concern. What matters is the trend across several tests over time.
🔀 What ART Doesn't Cover
ART suppresses HIV specifically. It doesn't protect against anything else.
- Bacterial STIs: Gonorrhoea, chlamydia, syphilis don't care about your viral load. If you're hooking up regularly, 90-day testing is still the standard — throat and arse swabs, not just urine. If you're very active, 6–8 weeks is closer to best practice.
- Viral STIs: HPV, Hep A/B, Mpox — these sit in a different category entirely. Vaccines close that gap. If you're not current, the vaccine guide has a quick checklist.
- Your partners' other risks: U=U covers HIV transmission. It doesn't make anyone bullet-proof against the rest of the panel. Their testing rhythm still applies alongside whatever prevention stack they're running.
🔀 Switching Regimens
If your first regimen causes persistent side effects, interacts with other medications, or a resistance test changes the picture, switching is normal — not a sign anything went wrong. Most people stay on their first regimen for years; some change once or twice. The options are there.
Two things worth knowing: never stop ART without talking to your doctor first — the rebound and resistance risk is the same as prolonged missed doses. And when you do switch, the new regimen needs the same runway to confirm suppression, unless your previous viral load was already confirmed undetectable.
⚠️ One Overlap Worth Knowing
The injectable PrEP (Cabotegravir / Apretude) belongs to the same drug class as some ART regimens — specifically the integrase inhibitors. If you were on injectable PrEP and test HIV-positive, your treatment plan needs specialist input. Not all regimens work in that situation. Tell your doctor about the Cabotegravir immediately and before any treatment decision is made. The HIV Diagnosis guide covers what your first appointment should look like.
Related: